JP6324381B2 - 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー - Google Patents

抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー Download PDF

Info

Publication number
JP6324381B2
JP6324381B2 JP2015525570A JP2015525570A JP6324381B2 JP 6324381 B2 JP6324381 B2 JP 6324381B2 JP 2015525570 A JP2015525570 A JP 2015525570A JP 2015525570 A JP2015525570 A JP 2015525570A JP 6324381 B2 JP6324381 B2 JP 6324381B2
Authority
JP
Japan
Prior art keywords
treatment
egfr
nsclc
lung cancer
cetuximab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015525570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015527341A (ja
JP2015527341A5 (https=
Inventor
ヘンリー チシャン リ
ヘンリー チシャン リ
メンメン ヤン
メンメン ヤン
Original Assignee
クラウン バイオサイエンス インコーポレイテッド（タイカン）
クラウン バイオサイエンス インコーポレイテッド（タイカン）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クラウン バイオサイエンス インコーポレイテッド（タイカン）, クラウン バイオサイエンス インコーポレイテッド（タイカン） filed Critical クラウン バイオサイエンス インコーポレイテッド（タイカン）
Publication of JP2015527341A publication Critical patent/JP2015527341A/ja
Publication of JP2015527341A5 publication Critical patent/JP2015527341A5/ja
Application granted granted Critical
Publication of JP6324381B2 publication Critical patent/JP6324381B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015525570A 2012-07-31 2013-07-31 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー Expired - Fee Related JP6324381B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2012/079399 2012-07-31
CN2012079399 2012-07-31
PCT/US2013/053091 WO2014028221A1 (en) 2012-07-31 2013-07-31 Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug

Publications (3)

Publication Number Publication Date
JP2015527341A JP2015527341A (ja) 2015-09-17
JP2015527341A5 JP2015527341A5 (https=) 2016-07-07
JP6324381B2 true JP6324381B2 (ja) 2018-05-16

Family

ID=50101405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015525570A Expired - Fee Related JP6324381B2 (ja) 2012-07-31 2013-07-31 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー

Country Status (5)

Country Link
US (1) US9921222B2 (https=)
EP (1) EP2879712B1 (https=)
JP (1) JP6324381B2 (https=)
ES (1) ES2668861T3 (https=)
WO (1) WO2014028221A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073015B (zh) * 2014-09-16 2020-07-21 艾伯维公司 用于治疗吸烟者中的非小细胞肺癌的维利帕尼与卡铂和紫杉醇的组合
CN110520543A (zh) * 2017-03-29 2019-11-29 中美冠科生物技术（太仓）有限公司 确定胃癌对西妥昔单抗敏感性的系统和方法
CN112813164A (zh) * 2021-01-18 2021-05-18 四川省肿瘤医院 Ereg促进nsclc细胞对egfr-tki产生耐药性原因的验证方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5942602A (en) 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
EP1622941A2 (en) 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
CA2560305C (en) 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
CA2612183C (en) 2005-06-28 2015-08-11 Genentech, Inc. Egfr and kras mutations
DK1951759T3 (da) 2005-11-12 2010-05-10 Lilly Co Eli Anti-EGFR-antistoffer
WO2008140493A2 (en) 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
KR100968591B1 (ko) 2007-06-14 2010-07-08 한국과학기술연구원 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도
US20100009390A1 (en) 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
CN102164960A (zh) 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
WO2010080463A1 (en) 2008-12-18 2010-07-15 Imclone Llc Antibody humanization
KR101108642B1 (ko) 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
CA2777825A1 (en) 2009-10-28 2011-05-19 Abbott Biotherapeutics Corp. Anti-egfr antibodies and their uses
AU2010319322A1 (en) * 2009-11-13 2012-05-31 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
BR112012013148A2 (pt) 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag formulação farmacêutica e uso
JP2011144124A (ja) 2010-01-13 2011-07-28 Fujirebio Inc 活性型ｅｇｆｒ特異抗体
EP2566512A1 (en) 2010-05-04 2013-03-13 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
JP5965838B2 (ja) 2010-06-04 2016-08-10 東亞合成株式会社 抗体およびその利用
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
EP2603527A1 (en) 2010-08-10 2013-06-19 Glycotope GmbH Humanized egfr antibodies
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies

Also Published As

Publication number Publication date
EP2879712A4 (en) 2016-03-16
US9921222B2 (en) 2018-03-20
JP2015527341A (ja) 2015-09-17
ES2668861T3 (es) 2018-05-22
EP2879712B1 (en) 2018-04-25
EP2879712A1 (en) 2015-06-10
WO2014028221A1 (en) 2014-02-20
US20150168411A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
Lv et al. Value of 18F–FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients
Moehler et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
Viola et al. A validation study for the use of ROS1 immunohistochemical staining in screening for ROS1 translocations in lung cancer
Okines et al. Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
US20140109245A1 (en) Prostate cancer cell lines, gene signatures and uses thereof
EP1861715A2 (en) Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2014028222A1 (en) Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug
US10442862B2 (en) Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents
Kogo et al. Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor
Nakata et al. EGFR gene copy number alteration is a better prognostic indicator than protein overexpression in oral tongue squamous cell carcinomas
JP6324381B2 (ja) 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー
Mimae et al. Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas
JP2016540993A (ja) タンパク質生体マーカー及びその使用
Zhu et al. Primary NTRK-rearranged spindle cell neoplasm of the lung: a clinicopathologic and molecular analysis of 3 cases
CN104168921B (zh) 用于为抗egfr药物治疗鉴定非小细胞肺癌患者的组织学标志物
Wang et al. Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients
Chen et al. Combined analysis of EGFR and PTEN status in patients with KRAS wild-type metastatic colorectal cancer
CN105188742A (zh) Egfr生物标志物用于利用抗egfr试剂治疗胃癌的用途
González-Gualda et al. Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome
JP2013521487A (ja) Ｅｇｆｒ阻害剤を用いる処置のための患者を選択する方法
US20150218647A1 (en) Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug
Haapala Rapid Identification of Brain Tumours with Differential Mobility Spectrometry
US12560611B2 (en) Ratio between PLGF and sFLt1 is predictive for neural invasion in patients suffering from pancreatic cancer
CN105407913A (zh) 用于鉴定可用抗egfr药物治疗的食管癌患者的生物标志物
WO2024235337A1 (zh) Hr阳性her2阴性乳腺癌的分型系统和方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150610

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180410

R150 Certificate of patent or registration of utility model

Ref document number: 6324381

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees